

DESCRIPTION

Source	Mouse myeloma cell line, NS0-derived Val38-Ala270, with a C-terminal 6-His tag Accession # EDM04022
N-terminal Sequence Analysis	Val38
Predicted Molecular Mass	27.5 kDa

SPECIFICATIONS

SDS-PAGE	33-40 kDa, reducing conditions
Activity	Measured by its ability to inhibit IL-9-induced proliferation of TS1 mouse helper T cells. The ED ₅₀ for this effect is 0.25-1.25 µg/mL in the presence of rIL-9 at 50 ng/mL.
Endotoxin Level	<0.01 EU per 1 µg of the protein by the LAL method.
Purity	>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS. See Certificate of Analysis for details.

PREPARATION AND STORAGE

Reconstitution	Reconstitute at 200 µg/mL in sterile PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none"> ● 12 months from date of receipt, -20 to -70 °C as supplied. ● 1 month, 2 to 8 °C under sterile conditions after reconstitution. ● 3 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

The IL-9 receptor alpha protein is a member of the type I cytokine receptor family. It is a 62 kDa IL-9 receptor subunit (previously Gfi-2, designated CD129) that binds IL-9 and pairs with the 64 kDa cytokine receptor common γ-chain to allow cell signaling (1 - 3). The 467 amino acid (aa) rat IL-9 Rα precursor is predicted to contain a 37 aa signal sequence, a 232 aa extracellular domain (ECD) with four conserved cysteine residues in its N-terminal region, a fibronectin type III domain and a WSXWS motif, a 21 aa transmembrane (TM) domain, and a 177 aa cytoplasmic domain with a Box 1 JAK-binding motif (1, 2, 4). A potential isoform contains a 36 aa sequence that is substituted for the TM and cytoplasmic domains (5). The ECD of rat IL-9 Rα shares 86%, 63%, 66%, 63% and 59% aa identity with the ECD of mouse, human, equine, canine and bovine IL-9 Rα, respectively. Mast cells, germinal center and B-1b B cells, T cell blasts, and myeloid progenitors express IL-9 R (1, 6 - 8). The primary functions of IL-9 have been difficult to determine due to the cross-functionality and cross-induction of cytokines. IL-9 production by regulatory T cells (T-regs), however, is crucial for mast cell recruitment and differentiation, which in turn is crucial for tolerance of allografts (7). Genetic deletion and transgenic expression of IL-9 and other cytokines has also demonstrated the role of IL-9 in mastocytosis, eosinophilia and B cell infiltration of the lung in a mouse asthma-like model, while IL-9 induction of IL-13 is responsible for eosinophil recruitment and mucous upregulation (8 - 10).

References:

1. Knoops, L. and J-C. Renauld (2004) Growth Factors **22**:207.
2. Flubacher, M.M. *et al.* (1994) J. Virol. **68**:7709.
3. Demoulin, J-B. *et al.* (1996) Mol. Cell. Biol. **16**:4710.
4. Swissprot Accession # Q63216
5. Entrez Accession # EDM04023
6. Fawaz, L.M. *et al.* (2007) J. Allergy Clin. Immunol. **120**:1208.
7. Lu, L-F. *et al.* (2006) Nature **442**:997.
8. Steenwinkel, V. *et al.* (2007) J. Immunol. **178**:3244.
9. Townsend, M.J. *et al.* (2000) Immunity **13**:573.
10. Fallon, P.G. *et al.* (2002) Immunity **17**:7.